Harry Erba, MD, PhD, Duke University, Durham, NC, shares some insights into MyeloMATCH: the National Cancer Institute (NCI) Myeloid Malignancies Molecular Analysis for Therapy Choice precision medicine clinical trial, which aims to rapidly advance therapeutic options for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Using advanced DNA sequencing technologies, Dr Erba explains that MyeloMATCH will allow patients to enrol in specific targeted treatment trials and overcome the challenge of long waiting periods, providing patients with treatment options at an early stage in disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.